Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of therapies for kidney diseases. The company's lead product, Auryxia, is a ferric citrate formulation designed to manage serum phosphorus levels in adults with chronic kidney disease, particularly those on dialysis, as well as to treat iron deficiency anemia in non-dialysis patients. Additionally, Akebia is advancing vadadustat, an oral therapy that targets anemia associated with chronic kidney disease, currently in Phase III clinical development. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various regions, including the United States and Japan. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing medicines for patients with kidney disease in the United States. Its primary product, Auryxia, is an oral iron-based medication that effectively controls serum phosphorus levels in patients with chronic kidney disease (CKD) undergoing dialysis and treats iron deficiency anemia in adults with CKD not on dialysis. The company supports independent investigator-sponsored research involving Auryxia and offers various patient assistance programs, including reimbursement help and copay support. Founded in 1998 and headquartered in Boston, Massachusetts, Keryx Biopharmaceuticals has established strategic partnerships with organizations in Japan for the development and commercialization of its products. As of December 2018, Keryx operates as a subsidiary of Akebia Therapeutics, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.